🇺🇸 FDA
Pipeline program

TTI-101

2022-0625

Phase 2 small_molecule terminated

Quick answer

TTI-101 for Head and Neck Squamous Cell Carcinoma is a Phase 2 program (small_molecule) at Tvardi Therapeutics with 1 ClinicalTrials.gov record(s).

Program details

Company
Tvardi Therapeutics
Indication
Head and Neck Squamous Cell Carcinoma
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials